3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
14
Gemcitabine
8
Docetaxel
7
Nivolumab
6
durvalumab
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
atezolizumab
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
sargramostim
3
aldesleukin
3
Specimen Handling
3
Radiotherapy
3
Paclitaxel
3
Ipilimumab
3
Fulvestrant
3
Cisplatin
3
Carboplatin
3
venetoclax
2
temsirolimus
2
talazoparib
2
spartalizumab
2
olaparib
2
liposomal doxorubicin
2
fludarabine phosphate
2
cabozantinib
2
budigalimab
2
avelumab
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
futibatinib
×
Breast
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled